Epitope Switching as a Novel Escape Mechanism of HIV to CCR5 Monoclonal Antibodies

被引:5
|
作者
Jekle, Andreas [1 ]
Chhabra, Milloni [1 ]
Lochner, Adriane [1 ]
Meier, Sonja [1 ]
Chow, Eugene [1 ]
Brandt, Michael [2 ]
Sankuratri, Surya [1 ]
Cammack, Nick [1 ]
Heilek, Gabrielle [1 ]
机构
[1] Roche Palo Alto LLC, Palo Alto, CA 94304 USA
[2] Roche Diagnost GmbH, Penzberg, Germany
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTORS; ANTIVIRAL ACTIVITY; HIGHLY POTENT; GP120; BINDING; TYPE-1; ENTRY; VIRAL ENTRY; INFECTION; INHIBITION; RESISTANCE;
D O I
10.1128/AAC.00841-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In passaging experiments, we isolated HIV strains resistant to MAb3952, a chemokine (C-C motif) receptor 5 (CCR5) monoclonal antibody (MAb) that binds to the second extracellular domain (extracellular loop 2 [ECL-2]) of CCR5. MAb3952-resistant viruses remain CCR5-tropic and are cross-resistant to a second ECL-2-specific antibody. Surprisingly, MAb3952-resistant viruses were more susceptible to RoAb13, a CCR5 antibody binding to the N terminus of CCR5. Using CCR5 receptor mutants, we show that MAb3952-resistant virus strains preferentially use the N terminus of CCR5, while the wild-type viruses preferentially use ECL-2. We propose this switch in the CCR5 binding site as a novel mechanism of HIV resistance.
引用
收藏
页码:734 / 741
页数:8
相关论文
共 50 条
  • [31] Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody
    Jacobson, Jeffrey M.
    Thompson, Melanie A.
    Lalezari, Jacob P.
    Saag, Michael S.
    Zingman, Barry S.
    D'Ambrosio, Paul
    Stambler, Nancy
    Rotshteyn, Yakov
    Marozsan, Andre J.
    Maddon, Paul J.
    Morris, Stephen A.
    Olson, William C.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (10) : 1481 - 1487
  • [32] CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities
    Wilkin, Timothy J.
    Gulick, Roy M.
    ANNUAL REVIEW OF MEDICINE, VOL 63, 2012, 63 : 81 - 93
  • [33] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [34] Targeting CCR5 for anti-HIV research
    W.-G. Gu
    X.-Q. Chen
    European Journal of Clinical Microbiology & Infectious Diseases, 2014, 33 : 1881 - 1887
  • [35] Treatment of HIV infection with the CCR5 antagonist maraviroc
    Kromdijk, Wiete
    Huitema, Alwin D. R.
    Mulder, Jan Willem
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1215 - 1223
  • [36] CCR5 inhibitors in HIV-1 therapy
    Dorr, Patrick
    Perros, Manos
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
  • [37] Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate
    Henrich, Timothy J.
    Tsibris, Athe M. N.
    Lewine, Nicolas R. P.
    Konstantinidis, Ioannis
    Leopold, Kay E.
    Sagar, Manish
    Kuritzkes, Daniel R.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 55 (04) : 420 - 427
  • [38] Analyses of Anti-HIV Type 1 Activity of a Small CCR5 Peptide Antagonist
    Wang, Fang Yu
    He, Shu Ya
    Zhang, Zhi Jian
    He, Li Fang
    Chen, Xiao Wei
    Teng, Tao
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : 1111 - 1115
  • [39] Targeting CCR5 for anti-HIV research
    Gu, W. -G.
    Chen, X. -Q.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2014, 33 (11) : 1881 - 1887
  • [40] Clinical use of CCR5 inhibitors in HIV and beyond
    Gilliam, Bruce L.
    Riedel, David J.
    Redfield, Robert R.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9